Leading expert views on the role of MRD in patient care

The body of evidence supporting MRD assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on how MRD results influence clinical practice decisions.


Dr. Jeffrey Wolf discusses the test performance criteria of an ideal MRD assay and his personal experience using MRD in clinical practice.

Dr. Ola Landgren discusses the prognostic value of MRD and its important role in myeloma due to the deep responses now available.

Dr. Hervé Avet-Loiseau explores prognostic factors in myeloma treatment and the future of MRD.

Dr. Nikil Munshi explains the role of MRD in myeloma treatment and whether MRD negativity should be a considered as a treatment goal.

Publication

Jeffrey Wolf, Rafael Fonseca, and Lori Muffly

In this roundtable monograph published in Clinical Advances in Hematology and Oncology, three thought-leading clinicians provide case studies and share their perspectives on the role of MRD assessment in clinical practice. (This study was sponsored by Adaptive Biotechnologies.)

View Article Arrow


This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.

Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz